Intervention

TAK-041

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

2 shown

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable SchizophreniaNCT03319953 · 2017-12-21

COMPLETED

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyNCT02748694 · 2016-05-09

COMPLETED

Common conditions

Healthy Volunteers1 Schizophrenia1 Stable Schizophrenia1

Leading sponsors

Neurocrine Biosciences 2

Trial status mix

COMPLETED2

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.